A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors

American Journal of Transplantation

Volumn 14, Issue 11, 2014, Pages 2577-2587

  Fink, S E K ^a,b   Gandhi, M K ^a,c   Nourse, J P ^a   Keane, C ^a,c   Jones, K ^a,c   Crooks, P ^a,c   Johrens K ^b   Korfel, A ^b   Schmidt, H ^d   Neumann, S ^e   Tiede, A ^f   Jager U ^g   Duhrsen U ^h   Neuhaus, R ^b   Dreyling, M ⁱ   Borchert, K ^j   Sudhoff T ^k   Riess, H ^b   Anagnostopoulos, I ^b   Trappe, R U ^b,l,m  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j UNIVERSITY OF ROSTOCK   (Germany)

^k Department of Internal Medicine   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m Diako Hospital   (Germany)

more..

Author keywords

Kidney transplantation nephrology; molecular biology: micro RNA; posttransplant lymphoproliferative disorder (PTLD); translational research science

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 17; MICRORNA 21; MICRORNA 221; MICRORNA 92; MYC PROTEIN; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CENTRAL NERVOUS SYSTEM DISEASE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; PLASMACYTOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY CENTRAL NERVOUS SYSTEM POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LATENCY; VIRUS TYPING; CENTRAL NERVOUS SYSTEM TUMOR; GENETICS; LYMPHOPROLIFERATIVE DISEASE; TRANSFORMED CELL LINE; VIROLOGY;

CELL LINE, TRANSFORMED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICRORNAS; TRANSCRIPTOME;

EID: 84911991456     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12858     Document Type: Article

References (55)

1. Evens AM, Choquet S, Kroll-Desrosiers AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern era. Am J Transplant 2013; 13: 1512-1522.
2. Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: Presentation and outcome. Transplantation 2003; 76: 930-937.
3. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ., Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004; 121: 246-253.
4. Phan TG, O'Neill BP, Kurtin PJ., Posttransplant primary CNS lymphoma. Neuro Oncol 2000; 2: 229-238.
5. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
6. Nourse JP, Jones K, Gandhi MK., Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am J Transplant 2011; 11: 888-895.
7. Cavaliere R, Petroni G, Lopes MB, Schiff D;, International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: An International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010; 116: 863-870.
8. Maeda E, Akahane M, Kiryu S, et al. Spectrum of Epstein-Barr virus-related diseases: A pictorial review. Jpn J Radiol 2009; 27: 4-19.
9. Rickinson AB, Kieff E., Epstein-Barr virus. In:, Knipe DM, Howley PM, Griffin DE, et al. eds. Fields virology. Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 2575-2627.
10. Pachter JS, de Vries HE, Fabry Z., The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003; 62: 593-604.
11. Muldoon LL, Alvarez JI, Begley DJ, et al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab 2013; 33: 13-21.
12. Bell AI, Groves K, Kelly GL, et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 2006; 87 (Pt 10): 2885-2890.
13. Iorio MV, Croce CM., MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856.
14. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28-40.
15. Navarro MD, Lopez-Andreu M, Rodriguez-Benot A, Aguera ML, Del Castillo D, Aljama P., Cancer incidence and survival in kidney transplant patients. Transplant Proc 2008; 40: 2936-2940.
16. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113: 3754-3764.
17. Edwards RH, Marquitz AR, Raab-Traub N., Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 2008; 82: 9094-9106.
18. Nourse JP, Crooks P, Keane C, et al. Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples. J Virol Methods 2012; 184: 46-54.
19. Swerdlow SHWS, Chadburn A, Ferry JA., Post-transplant lymphoproliferative disorders. In:, Swerdlow SH, Campo E, Harris NL, et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: International Agency for Research on Cancer (IRAC), 2008, pp. 343-439.
20. Feederle R, Linnstaedt SD, Bannert H, et al. A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog 2011; 7: e1001294.
21. Barth S, Pfuhl T, Mamiani A, et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 2008; 36: 666-675.
22. Cavaliere R, Petroni G, Lopes MB, Schiff D., Primary central nervous system post-transplantation lymphoproliferative disorder: An International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 2010; 116: 863-870.
23. Oudejans JJ, Jiwa M, van den Brule AJ, et al. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 1995; 147: 923-933.
24. Kelly GL, Milner AE, Tierney RJ, et al. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol 2005; 79: 10709-10717.
25. Montone KT, Hodinka RL, Salhany KE, Lavi E, Rostami A, Tomaszewski JE., Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod Pathol 1996; 9: 621-630.
26. Takada K, Ono Y., Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 1989; 63: 445-449.
27. Lassoued S, Gargouri B, Feki EL, Ael F, Attia H, Van Pelt J., Transcription of the Epstein-Barr virus lytic cycle activator BZLF-1 during oxidative stress induction. Biol Trace Elem Res 2010; 137: 13-22.
28. Feederle R, Kost M, Baumann M, et al. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 2000; 19: 3080-3089.
29. Gutsch DE, Marcu KB, Kenney SC., The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters. Cell Mol Biol (Noisy-le-grand) 1994; 40: 747-760.
30. Hong GK, Kumar P, Wang L, et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005; 79: 13984-13992.
31. Jones RJ, Seaman WT, Feng WH, et al. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int J Cancer 2007; 121: 1274-1281.
32. Hinrichs C, Wendland S, Zimmermann H, et al. IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: A longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transpl Int 2011; 24: 892-903.
33. Cai X, Schafer A, Lu S, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006; 2: e23.
34. Cosmopoulos K, Pegtel M, Hawkins J, et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 2009; 83: 2357-2367.
35. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A 2010; 107: 6328-6333.
36. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006; 103: 7024-7029.
37. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR., Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol 2010; 84: 11670-11678.
38. Medina PP, Nolde M, Slack FJ., OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90.
39. Sandhu SK, Fassan M, Volinia S, et al. B-cell malignancies in microRNA Emu-miR-1792 transgenic mice. Proc Natl Acad Sci U S A 2013; 110: 18208-18213.
40. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME., The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010; 17: F19-F36.
41. Buechner J, Tomte E, Haug BH, et al. Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer 2011; 105: 296-303.
42. Mishima T, Mizuguchi Y, Kawahigashi Y, Takizawa T, Takizawa T., RT-PCR-based analysis of microRNA (miR-1 and -124) expression in mouse CNS. Brain Res 2007; 1131: 37-43.
43. Zhang MC, Lv Y, Qi YT, et al. Knockdown and overexpression of miR-219 lead to embryonic defects in zebrafish development. Fen Zi Xi Bao Sheng Wu Xue Bao 2008; 41: 341-348.
44. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V., Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 2004; 5: R13.
45. Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E., Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 2011; 13: 1090-1098.
46. Yeung ML, Yasunaga J, Bennasser Y, et al. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res 2008; 68: 8976-8985.
47. Jindra PT, Bagley J, Godwin JG, Iacomini J., Costimulation-dependent expression of microRNA-214 increases the ability of T cells to proliferate by targeting Pten. J Immunol 2010; 185: 990-997.
48. Li LM, Hou DX, Guo YL, et al. Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product-induced apoptosis delay in monocytes. J Immunol 2011; 186: 2552-2560.
49. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T., Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007; 98: 1914-1920.
50. Takaoka Y, Shimizu Y, Hasegawa H, et al. Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min) mice. PLoS ONE 2012; 7: e42137.
51. Orom UA, Nielsen FC, Lund AH., MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-471.
52. Rane S, He M, Sayed D, et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009; 104: 879-886.
53. Richard DE, Berra E, Pouyssegur J., Angiogenesis: How a tumor adapts to hypoxia. Biochem Biophys Res Commun 1999; 266: 718-722.
54. Paramore A, Frantz S., Bortezomib. Nat Rev Drug Discov 2003; 2: 611-612.
55. Bu R, Hussain AR, Al-Obaisi KA, Ahmed M, Uddin S, Al-Kuraya KS., Bortezomib inhibits proteasomal degradation of IkappaBalpha and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55: 415-424.